Revisiones para NeuroEPO in patients with Parkinson disease stage II-III | Registro Público Cubano de Ensayos Clínicos

Comparando dos revisiones:

--- 11 Junio 2018 - 2:53pm por CIM
+++ 31 Julio 2023 - 3:32pm por CIM
-/02/01
+/07/31
-/02/01
+/07/31

Revisión de 31 Julio 2023 - 3:32pm

NeuroEPO in patients with Parkinson disease stage II-III

General information

Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.

Acronym of Public Title:

mAkEUP

Scientific title:

Assessing the efficacy and safety of nasal NeuroEpo management in Patients disease with Parkinson stage II-III

Acronym of Scientific Title:

mAkEUP

Secondary indentifying numbers:

Not applicable

Issuing authority of the secondary identifying numbers:

169

Source(s) of monetary or material support:

Center of Molecular Immunology (CIM) Ministry of Public Health (MINSAP)

Authorization for beginning

Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.

Regulatory instance to authorize the initiation of the study:

Center for State Control of Drugs, Medical Devices and Equipment (CECMED)

Authorization date :

09/06/2018

Reference number:

0607/05.007.17BA

Principal investigator

Section to complete information about Email address, telephone number and postal address of the Principal Investigator.

First name:

Ivonne

Last name:

Pedroso Ibañez

Medical Specialty :

First degree specialist in Neurology

Affiliation:

International Center of Neurologic Restoration (CIREN)

Postal address:

Ave. 25 No. 15805, e/ 158 y160. Cubanacan, Playa

City:

Havana

País:

Cuba

Zip Code:

11600

Telephone:

+53-72736777

Email address:

ivon@neuro.ciren.cu

Clinical sites to participate

Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.

Countries of recruitment:

Cuba

Clinical sites:

Not applicable

Research ethics committees:

International Center of Neurologic Restoration (CIREN), February 01, 2017

Recruitment status

Section to complete information about the recruitment status and the date of first enrolment subject

Recruitment status:

Recruiting

Date of first enrollment:

08/12/2017

Health condition and Intervention

Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).

Health condition(s) or Problem(s) studied:

Parkinson's disease stage II-III

Health condition(s) code:

Parkinson Diseases

Parkinsonian Disorders

Basal Ganglia Diseases

Brain Diseases

Central Nervous System Diseases

Nervous System Diseases

Movement Disorders

Neurodegenerative Diseases

Intervention(s):

Group A (experimental): 0.5 mg NeuroEPO by intranasal route, 3 times a week for 4 weeks (induction period) and, then continue with 1mg weekly for 20 weeks (maintenance period). Group B (experimental): 1.0 mg NeuroEPO by intranasal route, 3 times a week for 4 weeks (induction period) and then, continue with the same doses weekly for 20 weeks (maintenance period). Group C (control): Placebo. This group will be divide in two equal subgroups (one for each experimental group). The patients will receive the same doses, schema and administration route.

Intervention code:

Erythropoietin

Neuroprotective Agents

Administration, Intranasal

Placebos

Intervention keyword:

NeuroEPO

Outcomes and Timepoint

Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.

Primary outcome(s):

Total UPDRS Value (UPDRS scale). Measuring time: 9 months.

Key secondary outcomes:

Related to eficacy 1. UPDRS motor. measure by UPDRS III. Measuring time: 0, 6, 9 months 2. Daytime mobility fluctuations: measured by self-report. Measure by: Presence of on/off (on and off) dyskinesias (yes/no), dystonias (score), paradoxical fluctuations (score). Measuring time: 0, 6, 9 months 3. Total dose of dopaminergic stimulation. Measure by percentage. Measuring time: in each administration of the product. 4. Cognitive impairment. Measured by the DRS (Dementia Rating Scale) by Mattis. Measuring time:: 0, 9 months 5. Mental flexibility. Measured by the Trail Test (TMT). Measuring time: 0, 9 months 6. Working Memory. Measured by the TMT. Measuring time: 0, 9 months 7. Motor response rate. Measured by the TMT. Measuring time: 0, 9 months 8. Sustained attention. Measured by subtest 2 of the WAIS III Working Memory Index. Measuring time: 0, 9 months 9. Working memory. Measured by subtest 2 of the WAIS III Working Memory Index. Measuring time: 0, 9 months 10. Phonological verbal fluency. Measured by the Verbal Fluency Test (FAST). Measuring time: 0, 9 months 11. Semantic verbal fluency. Measured by FAST. Measuring time: 0, 9 months 12. Ability to alternate mental categories. Measured by FAST. Measuring time: 0, 9 months 13. Executive function. Measured by Litvan Frontal Assessment Battery (FAB). Measuring time: 0, 9 months 14. Selective attention (Measured by Stroop test). Measuring time:: 0, 9 months 15. Focused attention (Measured by Stroop test). Measuring time: 0, 9 months 16. Visuoconstructive function (Measured by Fig. De Rey). Measuring time: 0, 9 months 17. Visual memory (Measured by Fig. Of Rey). Measuring time:: 0, 9 months 18. Level of anxiety. Measured by the HADS (Hospital Anxiety and Depression Scale) Hospital Anxiety and Depression Scale. Measuring time: 0, 9 months 19. Level of depression. Measured by HADS. Measuring time: 0, 9 months Related to safety: 20. Adverse Events-AE (Severity of AE (serious or not), Type of AE (accordint to Regulation 45/2007 CECMED), Intensity of AE (mild, moderate, serious), Causality relationship (Very likely, Likely, possible, unlikely, unrelated or non-evaluable), Attitude about the drug (No change, dose reduction, temporary interruption of treatment, definitive discontinuation of treatment), Outcome (Reversible effect, irreversible effect, death, loss of patient follow-up)). Measuring time: in each evaluation at 6 and 9 months and in each administration of the product. 21. Laboratory test (Hemoglobin (Normal, abnormal), Hematocrit (Normal, abnormal), Platelet count (Normal, abnormal), Leukocyte count (Normal, abnormal), Glycemia (Normal, abnormal), TGO (Normal, abnormal), TGP (Normal, abnormal), GGT (Normal, abnormal), Creatinine, (Normal, abnormal), uric acid (Normal, abnormal), urea (normal, abnormal)). Measuring time: 0, 6 and 9 months. 22. Blood pressure (mm/Hg). Measuring time: in each evaluation at 0, 6 and 9 months and in each administration of the product.

Selection criterias

Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.

Gender:

Male/Female

Minimum age:

18 years

Maximum age:

None

Inclusion criteria:

1. Patients with Parkinson's disease, who meet the diagnostic criteria of BBL and stage II-III according to Hoehn and Yahr scale. 2. Patients older than 18 years. 3. One or more years of evolution of motor symptoms. 4. Good response to dopaminergic stimulation. 5. Acceptable general health status, not previous polygllobulia (Hto equal or lower than 50). 6. Patients who consent to participate in the study by signing the informed consent model.

Exclusion criteria:

1. Negative patient to participate in the study. 2. Presence of signs indicative of cognitive deterioration or psychiatric complications at the time of study. 3. Presence of accidents or other diseases during the therapeutic period that disqualify the patient to clinical trial. 4. Patients with known hypersensitivity to any component of the formulation. 5. Patients who are pregnant or breastfeeding. 6. Patients of childbearing potential not using contraceptive methods. 7. Patients with uncontrolled hypertension (systolic pressure mayor 180 mmHg and / or diastolic pressure mayor 120 mmHg). 8. Patients receiving treatment with immunosuppressants, androgens or anabolic steroids in the month prior to inclusion. 9. Patients with haematological diseases: sickle cell, myelodysplastic syndromes, coagulation disorders or active bleeding. 10. Patients with severe hyperparathyroidism. 11. Patients diagnosed with malignant tumor or anticancer therapy. 12. Patients with decompensated psychiatric illness. 13. Patients with alcoholism or drug addiction in the two years prior to the evaluation for inclusion.

Type of population:

Adults

Type of participant:

Patients

Study design

Section to complete information about the characteristics of the study design.

Type study:

Interventional

Purpose:

Treatment

Allocation:

Randomized controlled trial

Masking:

Double Blind

Control group:

Placebo

Study design:

Parallel

Phase:

2-3

Target sample size:

102

Contact for public queries

Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status

First Name:

Leslie

Last Name:

Perez Ruiz

Specialty:

Bachelor in Pharmaceutical Sciences

Affiliation:

Center of Molecular Immunology (CIM)

Postal Address:

Calle 216, esquina 15. Atabey, Playa

City:

Havana

País:

Cuba

Zip Code:

11600

Telephone:

+537-2143202 +5372143202

Email :

leslie@cim.sld.cu

Contact for scientific queries

Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.

First Name:

Ivonne

Last Name:

Pedroso Ibannez

Specialty:

First degree specialist in Neurology

Affiliation:

International Center of Neurologic Restoration (CIREN)

Postal Address:

Ave. 25 No. 15805, e/ 158 y160. Cubanacan, Playa

City:

Havana

País:

Cuba

Zip Code:

11600

Telephone:

+53-72736777 ext 722

Email :

ivon@neuro.ciren.cu

Registration and Update

Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).

Primary registry:

RPCEC

Unique ID number:

RPCEC00000233

Date of Registration in Primary Registry:

01/02/2017

Record Verification Date:

2023/07/31

Next update date:

2024/07/31

Link to the spanish version:

Click here

Ensayos Registrados

Proceso de Registro

NeuroEPO in patients with Parkinson disease stage II-III

Acerca del RPCEC

Recursos útiles